Tako je s tem dan danes.
Jasno je pokazalo, da je bil miokarditis po cepljenju (v tem primeru odmerek Moderna 2) višji! kot miokarditis po okužbi s sars-cov-2 pri osebah <40.
Več pa v članku.
Nature Medicine paper revisited: And it is shocking
vinayprasadmdmph.substack.com
No, spet nekdo linka neke komentarje znanstvenih člankov, ki krožijo po družabnih omrežjih in so priredba rezultatov ali pa vsaj antivaxer interpretacija.
Tole piše v članku, ne v komentarju članka - vsekakor avtorji na noben način ne predlagajo, da se populacija moških do 40 ne cepi:
Whilst myocarditis can be life-threatening, most vaccineassociated myocarditis events have been mild and self-limiting22. The risk observed here is small and confined to the 7-day period following vaccination, whereas the lifetime risk of morbidity and mortality following SARS-CoV-2 infection is substantial. Indeed, myocardial injury is very common in persons admitted to hospital with SARS-CoV-2 infection26, when evaluated systematically using high-sensitivity cardiac troponin tests27. Moreover, evidence of myocardial injury, irrespective of whether due to myocarditis or myocardial ischemia, is associated with a higher risk of in-hospital death28.
We estimate that the absolute number of excess myocarditis events in the 28days following a first dose of adenovirus or mRNA vaccine is between one and six per million persons vaccinated, and the excess risk following the second dose of the mRNA-1283 vaccine is ten per million. By contrast, we estimate 40 excess myocarditis events per million in the 28days following SARS-CoV-2 0 10 20 30 40 ChAdOx1 (first dose) ChAdOx1 (second dose) BNT162b2 (first dose) BNT162b2 (second dose) mRNA-1,273 (first dose) mRNA-1,273 (second dose) SARS-CoV-2 positive test Myocarditis Excess events 0 5 10 15 ChAdOx1 (first dose) ChAdOx1 (second dose) BNT162b2 (first dose) BNT162b2 (second dose) mRNA-1,273 (first dose) mRNA-1,273 (second dose) SARS-CoV-2 positive test Myocarditis (<40) Excess events 0 2 4 6 ChAdOx1 (first dose) ChAdOx1 (second dose) BNT162b2 (first dose) BNT162b2 (second dose) mRNA-1,273 (first dose) mRNA-1,273 (second dose) SARS-CoV-2 positive test Pericarditis Excess events 0 1,000 2,000 3,000 ChAdOx1 (first dose) ChAdOx1 (second dose) BNT162b2 (first dose) BNT162b2 (second dose) mRNA-1,273 (first dose) mRNA-1,273 (second dose) SARS-CoV-2 positive test Cardiac arrhythmia Excess events Number of excess events in the 1–28 days postvaccination/SARS-CoV-2 positive test per 1 million vaccinated/infected Fig. 2 | Number of excess events due to exposure per 1 million exposed, as reported in Supplementary Table 10. When IRR did not show a significant increase of incidence over the 1–28 days postvaccination or a SARS-CoV-2 positive test, absolute measures are not given. Nature Medicine |
www.nature.com/naturemedicine Articles Nature Medicine infection. The risks are more evenly balanced in younger persons aged up to 40 years, where we estimated the excess in myocarditis events following SARS-CoV-2 infection to be 10 per million with the excess following a second dose of mRNA-1273 vaccine being 15 per million.
www.dnevnik.si
jana.si
www.oe24.at
www.rki.de
rumble.com
